The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round ...

As part of the mandate, OMD will focus on improving Piramal Pharma’s market presence, brand awareness, consumer engagement, ...

Indian drugmakers prepare for US tariffs, emphasizing role in providing affordable medicines while navigating potential impacts and uncertainties.

Retail and banking stocks rose 0.5 per cent and 0.7 per cent, respectively. NEW DELHI: BSE(Rs. 2851.95 crore), HDFC Bank(Rs.

The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

OMD India will lead the strategic marketing and media efforts for the company's portfolio of OTC brands, including Lacto ...